COVAXIN human trials will take around 3 months to complete, AIIMS


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴ covaxin-human-trials-need-three-more-months-aiims
Another three months for remaining two phases of trial of Covaxin, as reported by AIIMS Director

India is on a fast track mode to develop a COVID-19 vaccine. Briefing media in New Delhi today, AIIMS Delhi Director Randeep Guleria informed that the two phases of Human trials will take around 3 months to complete.

AIIMS, Delhi has initiated the Human clinical trials today for the indigenously developed COVAXIN.Dr. Guleria informed that initially the human trial will be conducted on 100 people. Terming development of an indigenous vaccine as a great achievement, he informed that the medical institute has received an overwhelming response in terms of volunteer registration for the trials.

Dr. Guleria said that before administration of the vaccine multiple tests of the health volunteers will be done.

He affirmed that only healthy individuals aged between 12 to 65 years will be inducted in the trials.

Meanwhile the Government said , recovered people from Coronavirus crossed the seven lakh mark today. The Central Government today said, a total of 7,00087 people affected with COVID-19 have recovered in the country so far and with this the recovery rate reached to 62.61 per cent.

The Health and Family Welfare Ministry said, a total of 22 664 people recovered in the past 24 hours. Presently, the total number of active cases in the country is three lakh 90,459.

The Health Ministry said, a total of 40425 new cases of COVID-19 were reported in the country within 24 hours taking the total number of cases to 11,1843. This is the highest number of fresh cases reported in one day since the outbreak of COVID-19 pandemic in India. In the single day, 681 deaths were reported taking the nationwide toll to 27 497. However, the case fatality rate is continuously declining in the country and it reached 2.45 per cent.

Meanwhile, Indian Council of Medical Research, ICMR said that a total of two lakh 56039 tests of Corona virus samples were conducted by the various laboratories within 24 hours. So far, laboratories have conducted one crore 40,47908 tests. ICMR is continuously ramping up the testing facilities in the country. At present, a total of one thousand 268 laboratories across India are conducting the tests for COVID-19 including 890 government laboratories and 378 private laboratories' chains.

Our correspondent reports that in terms of recovery rate of Coronavirus cases, the top five States and Union Territories are - Ladakh, Delhi, Haryana, Rajasthan and Gujarat wherein the recovery rate is above 72 per cent. There are 18 States and Union Territories that have better recovery rates than the national average of 62.61 per cent. In terms of number of people recovered from COVID-19, Maharashtra is leading the tally followed by Tamil Nadu and Delhi. Five States and Union Territories - Manipur, Nagaland, Sikkim, Mizoram and Andaman Nicobar Islands have not reported any single death due to COVID-19.

There are 29 States and Union Territories which have lower fatality rate than the national average of fatality rate 2.45 per cent. In the total active cases, more than 67 per cent caseloads are from Maharashtra, Tamil Nadu, Karnataka, Andhra Pradesh and Uttar Pradesh.

Tags : #BharatBiotech #Covaxin #AIIMSDirector #ICMR #HumanTrialsCovaxin #AIIMS #RandeepGuleria #CovidVaccine #RecoveryRate

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026